Military Testosterone Screening: What the Labs Actually Mean

The Pentagon's Testosterone Initiative: What Clinicians Need to Know

Pete Hegseth's directive requiring annual testosterone screening for US military service members over 30 marks a significant moment in occupational health policy—and reveals a fundamental gap in how most institutions interpret hormone labs.

The announcement itself is straightforward: standardized screening to identify low testosterone in active-duty personnel. But the clinical story is far more complex. This policy creates an opportunity to discuss what testosterone screening actually measures, why reference ranges mislead most people, and how to interpret results in the context of individual health.

Understanding the Three Testosterone Measurements

When a lab orders "testosterone screening," three distinct values should appear:

Total testosterone: The sum of all testosterone in the bloodstream—bound to sex hormone-binding globulin (SHBG), bound to albumin, and free. Reference range typically 300–1000 ng/dL for adult males. This is what most conventional screenings measure.

Free testosterone: The unbound, biologically active fraction. Reference range roughly 8–30 pg/mL. This is what actually binds androgen receptors in tissue.

Bioavailable testosterone: Free testosterone plus albumin-bound testosterone. Often more clinically relevant than total testosterone alone, especially in men with high SHBG (athletes, thyroid disease, certain medications).

The military screening will almost certainly rely on total testosterone—the cheapest, most standardized metric. This is where interpretation becomes critical.

The Reference Range Trap

Conventional reference ranges are derived from population averages of men who walked into labs—many of whom are overweight, sedentary, or hypogonadal by modern standards. A "normal" result of 400 ng/dL sits at the 25th percentile of healthy, optimized men, yet falls comfortably within reference.

For military personnel—young, physically demanding occupations—a total testosterone level of 300–400 ng/dL likely indicates functional hypogonadism despite being "normal" by lab standards.

Optimal ranges for symptomatic benefit and performance:

• Total testosterone: 600–900 ng/dL
• Free testosterone: 15–25 pg/mL
• Bioavailable testosterone: 100–200 ng/dL

These differ significantly from reference ranges because they reflect what produces measurable health outcomes, not what statistically qualifies as "not sick."

Why Baseline Testing Matters Before Intervention

The military screening creates a baseline—a critical prerequisite for any subsequent treatment. Here's why baseline testing must be comprehensive:

1. Establish pre-intervention hormone profile — Before any peptide therapy (GHRH agonists, sermorelin), testosterone replacement, or HCG use, you need documented baseline values. This allows assessment of natural production capacity and informs whether exogenous support will suppress endogenous axis function.

2. Assess SHBG status — High SHBG (seen in cardiovascular athletes, certain thyroid states) means total testosterone will be misleading. Two men with 500 ng/dL total can have wildly different free testosterone if SHBG differs.

3. Rule out secondary causes — Low testosterone can reflect:

• Pituitary insufficiency (check LH, FSH)
• Thyroid dysfunction (TSH, free T3, free T4)
• Metabolic syndrome/insulin resistance (fasting glucose, HbA1c, lipids)
• Elevated cortisol or DHEA-S suppression
• Nutritional deficiency (zinc, magnesium, vitamin D3)

A single testosterone value without this context is incomplete data.

The Endocrine Cascade: Why One Hormone Matters

Testosterone doesn't exist in isolation. The hypothalamic-pituitary-gonadal (HPG) axis is tightly regulated:

• GnRH (gonadotropin-releasing hormone) → pituitary
• LH and FSH → testicular stimulation
• Testosterone and inhibin → negative feedback

Screening soldiers identifies low testosterone but doesn't diagnose why. Is it primary testicular failure? Secondary (central) hypogonadism? Or functional hypogonadism from overtraining, sleep deprivation, stress (elevated cortisol), or metabolic dysfunction?

The answer determines whether testosterone replacement, lifestyle optimization, peptide support of the GnRH-LH-testosterone axis, or supplemental support (zinc, magnesium glycinate, vitamin D3/K2) is appropriate.

Labs Beyond Testosterone

Intelligent testosterone screening should include:

| Marker | Why It Matters | Optimal Range | |--------|---|---| | LH/FSH | Differentiates primary vs secondary hypogonadism | LH 2–9 mIU/mL, FSH 1–7 mIU/mL | | Estradiol | High E2 increases SHBG, suppresses LH; low E2 impacts mood, bone | 20–40 pg/mL (free T outweighs E2 at this range) | | DHEA-S | Adrenal reserve; correlates with longevity | 200–400 mcg/dL | | Cortisol (24h urine or AM) | Chronic elevation suppresses testosterone | <15 mcg/dL (AM), <30 mcg/24h (urine) | | TSH, free T3, free T4 | Hypothyroidism reduces testosterone and SHBG | TSH <2.0 mIU/L; free T3 >3.5 pg/mL | | Metabolic panel | Obesity, insulin resistance suppress testosterone | Fasting glucose <95 mg/dL, HbA1c <5.5% | | Lipids, inflammatory markers | Cardiovascular risk and inflammation both suppress testosterone | HDL >40 mg/dL, hsCRP <1 mg/L |

Peptides and Natural Testosterone Recovery

For service members identified with low testosterone, the choice isn't binary: replace testosterone or do nothing.

GHRH agonists (sermorelin, tesamorelin) stimulate natural growth hormone and can secondarily improve testosterone through improved metabolic health. These preserve endogenous axis function—critical for personnel required to maintain fertility and natural hormone responsiveness.

HCG (human chorionic gonadotropin) directly stimulates Leydig cells to produce testosterone. When used alongside GHRH agonists, it prevents testicular atrophy and suppression of natural LH.

These approaches require baseline LH/FSH and testosterone to establish whether axis function can be preserved or whether exogenous replacement is necessary.

Synergistic Nutritional Support

Regardless of intervention choice, micronutrient sufficiency is non-negotiable:

• Magnesium glycinate (500 mg/day): Reduces cortisol, improves sleep (testosterone rises during deep sleep)
• Zinc (25–50 mg/day): Required for testosterone synthesis; deficiency directly suppresses LH
• Vitamin D3/K2 (2000–4000 IU D3, 180–360 mcg K2): Calcitriol regulates LH release; K2 supports cardiovascular health
• NAC (1200–1800 mg/day): Reduces chronic inflammation; supports glutathione synthesis
• Omega-3 (2–3 g/day): Anti-inflammatory; improves free testosterone/cortisol ratio
• Ashwagandha extract (300–600 mg/day): Reduces cortisol by 25–30%; improves testosterone in stressed populations
• Methylated B complex: Supports methylation cycles; deficiency elevates homocysteine (suppresses testosterone)

Bottom Line

The military's testosterone screening is a public health signal that occupational medicine has awakened to endocrine monitoring. But screening alone is diagnosis theater without interpretation.

For any service member (or any man) identified with low testosterone, the path forward requires: (1) comprehensive baseline labs including LH, FSH, DHEA-S, cortisol, thyroid, metabolics; (2) differentiation between primary, secondary, and functional hypogonadism; (3) lifestyle optimization (sleep, stress management, training recovery) before jumping to exogenous replacement; (4) consideration of axis-preserving approaches (peptides, HCG, micronutrient repletion); (5) serial retesting at 6–12 weeks to assess intervention efficacy.

Testosterone screening is the beginning of conversation, not the end of it.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.